Importer of Controlled Substances; Notice of Registration, 2619 [E9-732]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 10 / Thursday, January 15, 2009 / Notices
Clinical Services, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR § 1301.34, the above named
company is granted registration as an
importer of the basic class of controlled
substance listed.
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–731 Filed 1–14–09; 8:45 am]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
jlentini on PROD1PC65 with NOTICES
Importer of Controlled Substances;
Notice of Registration
By Notice dated October 6, 2008, and
published in the Federal Register on
October 14, 2008, (73 FR 60719),
Hospira Inc., 1776 North Centennial
Drive, McPherson, Kansas 67460–1247,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
Remifentanil (9739), a basic class of
controlled substance listed in schedule
II.
The company plans to import
Remifentanil for use in dosage form
manufacturing.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Hospira, Inc. to import the basic class of
controlled substance is consistent with
the public interest, and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971, at this time. DEA
has investigated Hospira, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
VerDate Nov<24>2008
18:58 Jan 14, 2009
Jkt 217001
the basic class of controlled substance
listed.
DEPARTMENT OF JUSTICE
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–732 Filed 1–14–09; 8:45 am]
Drug Enforcement Administration
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
BILLING CODE 4410–09–P
2619
By Notice dated October 2, 2008, and
published in the Federal Register on
October 8, 2008, (73 FR 58979), Clinical
Supplies Management, Inc., 342 42nd.
Street, South Fargo, North Dakota
58103, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
Sufentanil (9740), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance for clinical
trials, research, and analytical purposes.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Clinical Supplies Management, Inc. to
import the basic class of controlled
substance is consistent with the public
interest, and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Clinical Supplies
Management, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–733 Filed 1–14–09; 8:45 am]
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated October 2, 2008 and
published in the Federal Register on
October 8, 2008, (73 FR 58979), National
Center for Natural Products Research—
NIDA MProject, University of
Mississippi, 135 Coy Waller Complex,
University, Mississippi 38677, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule I:
Drug
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) ......
Frm 00112
Fmt 4703
Sfmt 4703
I
I
The company plans to cultivate
marihuana for the National Institute on
Drug Abuse for research approved by
the Department of Health and Human
Services.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
National Center for Natural Products
Research—NIDA MProject to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated National Center for Natural
Products Research—NIDA MProject to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–719 Filed 1–14–09; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
PO 00000
Schedule
E:\FR\FM\15JAN1.SGM
15JAN1
]]>Agencies
[Federal Register Volume 74, Number 10 (Thursday, January 15, 2009)]
[Notices]
[Page 2619]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-732]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration
By Notice dated October 6, 2008, and published in the Federal
Register on October 14, 2008, (73 FR 60719), Hospira Inc., 1776 North
Centennial Drive, McPherson, Kansas 67460-1247, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as an importer of Remifentanil (9739), a basic class of controlled
substance listed in schedule II.
The company plans to import Remifentanil for use in dosage form
manufacturing.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and 952(a) and determined that the
registration of Hospira, Inc. to import the basic class of controlled
substance is consistent with the public interest, and with United
States obligations under international treaties, conventions, or
protocols in effect on May 1, 1971, at this time. DEA has investigated
Hospira, Inc. to ensure that the company's registration is consistent
with the public interest. The investigation has included inspection and
testing of the company's physical security systems, verification of the
company's compliance with state and local laws, and a review of the
company's background and history. Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above
named company is granted registration as an importer of the basic class
of controlled substance listed.
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-732 Filed 1-14-09; 8:45 am]
BILLING CODE 4410-09-P
